IP Library Granted Patent US 12,024,533
Granted Patent B2
US 12,024,533 · App. 18/087,587 · Granted Jul 2, 2024

Antimicrobial organosilanes

Inventors: Gary Allred (Wake Forest, NC); Lanny Liebeskind (Atlanta, GA); William R. Cast (Fort Wayne, IN); Carl Hilliard (Henderson, NV)
Assignee: Topikos Scientific, Inc.
C07F7/1896
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,024,533
App. No.
18/087,587
Granted
Jul 2, 2024
Kind
B2
Abstract

Organosilicon quaternary ammonium compounds, their formulations, including powdered and solid formulations, and methods of use to treat infections in humans and animals.

Claims (43)

1. A quaternary ammonium compound of Formula:

wherein

a is 1, 2, 3, 4, 5, 6, 7 or 8;

R 1 is independently at each occurrence selected from the group consisting of C 6 -C 22 alkyl and C 6 -C 22 alkanoyl;

R 2 , R 3 , R 4 , R 22 , R 23 , and R 24 are independently at each occurrence selected from the group consisting of:

each R 21 is independently selected from the group consisting of C 1 -C 22 alkyl and C 2 -C 22 alkanoyl;

R 7 is independently at each occurrence selected from the group consisting of hydrogen, C 1 -C 8 alkyl, C 1 -C 8 hydroxyalkyl, and C 1 -C 8 alkanoyl;

R 8 and R 9 are independently at each occurrence selected from the group consisting of hydrogen, halogen, hydroxyl, N(R 7 ) 2 , CH 2 OR 7 , CON(R 7 ) 2 , COOR 7 , C(O)R 7 , C 1 -C 8 alkyl, C 1 -C 8 hydroxyalkyl, and C 1 -C 8 alkanoyl;

X 1 is NR 17 , CH 2 , CHOH, or C(O);

X 2 is C 1 -C 3 alkyl or C 1 -C 3 hydroxyalkyl;

R 16 is C 1 -C 4 alkyl;

R 17 is hydrogen, C 1 -C 8 hydroxyalkyl, or C 1 -C 8 alkanoyl;

X − is an anion or is absent if the quaternary amine is balanced with an internal anion; and

B + is a cation.

2. The quaternary ammonium compound of claim 1 , wherein X − is selected from the group consisting of chloride, fluoride, iodide, bromide, hydroxide, chlorite, chlorate, hydroxide, formate, acetate, lactate, benzoate, methane sulfonate, and salicylate anion.

3. The quaternary ammonium compound of claim 1 , wherein B + is selected from the group consisting of Na + , K + , Li + , Mg 2+ , and Ca 2+ .

4. The quaternary ammonium compound of claim 1 , wherein the compound is a zwitterion and X is absent.

5. The quaternary ammonium compound of claim 1 , wherein X 1 is NH or N(CH 2 CH 2 OH).

6. The quaternary ammonium compound of claim 1 , wherein X 2 is CH 2 CH 2 or CH 2 CH(OH)CH 2 .

7. The quaternary ammonium compound of claim 6 , wherein R 16 is CH 3 .

8. The quaternary ammonium compound of claim 7 , wherein R 1 is octadecyl.

9. The quaternary ammonium compound of claim 8 , wherein R 8 and R 9 are each CH 2 OH.

10. The quaternary ammonium compound of claim 9 , wherein a is 3.

11. The quaternary ammonium compound of claim 10 , wherein X 1 is NH or N(CH 2 CH 2 OH).

12. The quaternary ammonium compound of claim 1 selected from the group consisting of:

13. The quaternary ammonium compound of claim 1 of structure:

14. The quaternary ammonium compound of claim 1 of structure:

15. The quaternary ammonium compound of claim 1 of structure:

16. The quaternary ammonium compound of claim 1 of structure:

17. The quaternary ammonium compound of claim 1 of structure:

18. The quaternary ammonium compound of claim 1 of structure:

19. The quaternary ammonium compound of claim 1 of structure:

20. The quaternary ammonium compound of claim 1 of structure:

21. The quaternary ammonium compound of claim 1 of structure:

22. The quaternary ammonium compound of claim 1 of structure:

23. The quaternary ammonium compound of claim 1 of structure:

24. The quaternary ammonium compound of claim 1 of structure:

25. An antimicrobial composition comprising a quaternary ammonium compound of claim 1 and a pharmaceutically acceptable carrier.

26. The antimicrobial according to claim 25 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of alcohol, aqueous solution, and glycerin solution.

27. The antimicrobial composition of claim 26 , wherein the composition is suitable for topical delivery.

28. The antimicrobial composition of claim 25 , wherein the quaternary ammonium compound is

29. The antimicrobial composition of claim 25 , wherein the quaternary ammonium compound is

30. The antimicrobial composition of claim 25 , wherein the quaternary ammonium compound is

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2024
From: LIEBESKIND, LANNY; CAST, WILLIAM R.; HILLIARD, CARL
To: TOPIKOS SCIENTIFIC, INC.
Reel/Frame 067326/0019 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2024
From: ALLRED, GARY
To: SYNTHONIX, INC.
Reel/Frame 067326/0046 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2024
From: SYNTHONIX, INC.
To: TOPIKOS SCIENTIFIC, INC.
Reel/Frame 067326/0051 →
CHANGE OF NAME Recorded Mar 28, 2023
From: TOPIKOS PHARMACEUTICALS, INC.
To: TOPIKOS SCIENTIFIC, INC.
Reel/Frame 063185/0928 →
Continuity (5)
Continuation 17723168 · Apr 18, 2022
Continuation PCTUS2020056392 · Oct 19, 2020
Provisional Application 63014535 · Apr 23, 2020
Provisional Application 62923372 · Oct 18, 2019
Related Publication 20230143708A1 · May 11, 2023